Arsenal Medical announces treatment of first patient with NeoCast embolic biomaterial


Arsenal Medical has today announced enrolment of the first patient treated with the company’s investigational NeoCast embolic biomaterial for neurovascular conditions.

The patient was successfully embolised as part of the NeoCast first-in-human clinical trial—an open-label, multicentre study evaluating the early safety and feasibility of NeoCast for the embolisation of a patient’s brain tumour to facilitate surgical removal.

“With the first patient treated, we confirmed that the material characteristics exhibited in preclinical studies translated well to clinical practice,” said the study’s primary investigator Lee-Anne Slater (Monash Health, Melbourne, Australia). “NeoCast was responsive, controlled, and highly visible during injection, penetrating deep into and occluding the target vessels. NeoCast is a promising solution for neurovascular applications that would benefit from penetration into the microvasculature, such as chronic subdural haematomas and hypervascular tumours.”

NeoCast was purpose-built to address the limitations of existing embolic products for indications where deep penetration into the microvasculature is desired, an Arsenal press release details.

Developed with funding from the National Cancer Institute, NeoCast leverages shear-thinning science to preferentially reach the smallest vessels, and stop blood flow to tumours as well as injured or diseased tissues. The resulting biomaterial is easy to deploy and yields consistent performance, while eliminating harsh solvents commonly found in current liquid embolics, the release adds.

“We appreciate the hard work of Dr Slater and our other clinical investigators to enable this important milestone,” said Upma Sharma, president and CEO of Arsenal. “This successful deployment of NeoCast demonstrates our vision of harnessing the power of materials to build groundbreaking medical devices. We look forward to completing the first-in-human study, and confirming the potential of our materials to address areas of disease or injury that have previously been inaccessible or untreatable.”


Please enter your comment!
Please enter your name here